approval
saveCYLTEZO (ADALIMUMAB-ADBM) — FDA approval
community read0 votes
Sponsor: BOEHRINGER INGELHEIM. Form: INJECTABLE. Route: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalOct 16, 2025 · 350d ago
- approvalCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalMay 20, 2025 · 499d ago
- approvalCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalApr 30, 2024 · 884d ago
- approvalCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalJul 19, 2023 · 1170d ago
- approvalCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalJun 30, 2023 · 1189d ago
- approvalCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalMay 18, 2023 · 1232d ago
- approvalCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalMar 22, 2023 · 1289d ago
- approvalCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalMar 18, 2022 · 1658d ago
same company · ±60 days · 6
- approvalSYNJARDY: JARDIANCE (EMPAGLIFLOZIN) — FDA approvalOct 13, 2022
- approval(empagliflozin + metformin hydrochloride ER): SYNJARDY XR (EMPAGLIFLOZIN) — FDA approvalOct 13, 2022
- approval(empagliflozin + linagliptin + metformin hydrochloride) ER: TRIJARDY XR (EMPAGLIFLOZIN) — FDA approvalOct 13, 2022
- approval(empagliflozin + linagliptin): GLYXAMBI (EMPAGLIFLOZIN) — FDA approvalOct 13, 2022
- approvalSYNJARDY: SYNJARDY (EMPAGLIFLOZIN) — FDA approvalOct 13, 2022
- approvalspesolimab: SPEVIGO (SPESOLIMAB-SBZO) — FDA approvalSep 1, 2022
comments(0)
5-min edit window · permanent after that